Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | AMG 701 |
Trade Name | |
Synonyms | AMG-701|AMG701|BiTE Antibody AMG 701|Anti-BCMA/CD3 BiTE Antibody AMG 701 |
Drug Descriptions |
AMG 701 is a bi-specific T-cell engager (BiTE) antibody that simultaneously binds to BCMA (TNFRSF17) and CD3, and activates cytotoxic T-lymphocytes against tumor cells expressing BCMA, potentially inducing death of BCMA expressing tumor cells (NCI Drug Dictionary). |
DrugClasses | CD3 Antibody 107 TNFRSF17 Antibody 22 |
CAS Registry Number | NA |
NCIT ID | C147028 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
AMG 701 | AMG 701 | 0 | 1 |
AMG 701 + Lenalidomide | AMG 701 Lenalidomide | 0 | 0 |